These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1937 related articles for article (PubMed ID: 28445469)

  • 21. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR
    Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumour DNA in
    Cabanero M; Tsao MS
    Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
    Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
    Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red blood cells function as reservoirs of tumor DNA.
    Thompson JC; Li S; Jose JS; Predina J; Gupta A; Eruslanov E; Singhal S; Albelda SM; Mangalmurti NS
    Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L646-L650. PubMed ID: 38529551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
    Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
    J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.
    Nong J; Gong Y; Guan Y; Yi X; Yi Y; Chang L; Yang L; Lv J; Guo Z; Jia H; Chu Y; Liu T; Chen M; Byers L; Roarty E; Lam VK; Papadimitrakopoulou VA; Wistuba I; Heymach JV; Glisson B; Liao Z; Lee JJ; Futreal PA; Zhang S; Xia X; Zhang J; Wang J
    Nat Commun; 2018 Aug; 9(1):3114. PubMed ID: 30082701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
    Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
    PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Birkenkamp-Demtröder K; Christensen E; Nordentoft I; Knudsen M; Taber A; Høyer S; Lamy P; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2018 Apr; 73(4):535-540. PubMed ID: 28958829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
    Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
    Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
    Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.
    Nie K; Jia Y; Zhang X
    Tumour Biol; 2015 Jan; 36(1):7-19. PubMed ID: 25352029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
    Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 97.